Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
The V1V2 mRNA-LNP vaccine is highly immunogenic in mice and rhesus macaques, eliciting cross-clade functional antibodies capable of recognizing native Env, and may provide insights relevant to vaccine testing against other pathogens.
Abstract
Antibodies against the V1V2 domain of the HIV envelope glycoprotein have been identified as a potential correlate of reduced infection risk in three large HIV vaccine efficacy trials. Although vaccine-elicited anti-V1V2 antibodies do not mediate potent virus-neutralizing activities, they mediate Fc-dependent effector functions. Strategies that enhance the magnitude and quality of these responses may improve HIV vaccine efficacy.
We examined a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) vaccine encoding the V1V2 domain of CRF_01.AE244 on the 2J9C scaffold. Immunogenicity was assessed in three animal models: mice, rabbits, and rhesus macaques, following two or more immunizations. Antibody binding, cross-reactivity, and Fc-mediated functions were quantified using Luminex antigen-binding assays, virion- and cell-surface Env recognition assays, antibody-dependent cellular phagocytosis (ADCP), and Fc receptor binding.
In mice two doses of the V1V2 mRNA-LNP vaccine elicited robust, cross-reactive serum IgG responses that recognized soluble Env and native Env on cells and virions. Importantly, murine IgG2a antibodies were generated that displayed Fc-mediated activities. However, in rabbits the elicited responses were directed mainly against the scaffold, with minimal V1V2-specific antibodies even after four vaccinations. In contrast, rhesus macaques developed high-level V1V2-specific antibodies responses after two vaccinations, comparable to those observed in mice.
The V1V2 mRNA-LNP vaccine is highly immunogenic in mice and rhesus macaques, eliciting cross-clade functional antibodies capable of recognizing native Env. The marked species-dependent differences, most notably the weak V1V2 targeting in rabbits, underscore the importance of selecting appropriate animal models for preclinical HIV vaccine evaluation and may provide insights relevant to vaccine testing against other pathogens.
VA Merit Review I01BX005616, NIH R01 AI148327
Vaccines and Immunotherapy (VAC)
Results demonstrate that AZD6563, at reduced doses, matches the cellular immunogenicity of BNT162b2 while enhancing B cell cross-reactivity and TCR diversity in older adults, supporting its potential as a next-generation COVID-19 vaccine candidate.
Michael D. Powell, Nicholas G. Battaglia, Lee-Jah Chang et al.· Journal of Immunology· 0 citations
Investigating how the vaccine shapes the CD4+ T cell immunity and how these responses cooperate in reducing the acquisition found that DV1 DNA/ALVAC/gp120 vaccine elicited envelope-specific immunomodulatory Tr1 CD4+ T cells, and that total Tr1 responses were associated with a reduced risk of viral acquisition.
Massimiliano Bissa, S. Fourati, Sohyoung Kim et al.· Journal of Immunology· 0 citations
We evaluate the efficacy and immunogenicity of HIV clade A/E A244 envelope (Env) immunogens with the 23 amino acids of variable region 1 deleted (ΔV1) or retained (wild-type [WT]) in macaques. Only the ΔV1 regimen significantly reduces the risk of mucosal acquisition of clade C simian/human immunodeficiency virus (SHIV)1157(QNE)Y173H versus controls, providing 81% efficacy and leaving 10 of 12 immunized animals uninfected. ΔV1 vaccination induces higher systemic antibody-dependent cellular cytotoxicity (ADCC) targeting helical-V2 and anti-inflammatory myeloid cells, which, together with IL-17+NKp44+ innate lymphoid cells (ILCs) and systemic PD-1+ helper T cells, correlated with reduced infection risk. By contrast, WT immunization induces higher IL-15, CCR2+pDC, and gp70/V1V2-biased responses, which, along with mucosal IFN-γ+NKG2A-NKp44- ILCs, were associated with increased susceptibility. Ex vivo, ΔV1 gp120 reduced CCR5 expression on CD4+ T cells relative to WT gp120, consistent with the anti-inflammatory mucosal response by ΔV1-vaccine regimens in vivo. Thus, V1 deletion promotes an anti-inflammatory mucosal landscape less permissive to HIV seeding and dissemination following virus exposure.
Isabela Silva de Castro, Mohammad Arif Rahman, Massimiliano Bissa et al.· Cell Reports Medicine· 0 citations
Dengue virus (DENV) remains a major global health burden, with four antigenically distinct serotypes (DENV-1–4) posing a significant challenge for vaccine development. Dengue non-structural protein 1 (NS1) has been associated with additional protection and reduced disease severity, supporting its inclusion in vaccine design. In this study, we designed a consensus NS1 (cNS1) antigen by integrating sequence elements from all four DENV serotypes (78–89% amino acid identity) to enhance cross-serotype antigenic coverage. The cNS1 sequence was encoded as a nucleoside-modified mRNA and formulated in lipid nanoparticles (mRNA–LNPs). Immunization of BALB/c mice with a low dose (0.2 µg) of cNS1 mRNA–LNP induced broadly reactive NS1-specific IgG responses that recognized NS1 proteins from all four serotypes. In addition, the vaccine elicited interferon-γ (IFN-γ)–producing T cell responses against peptide pools derived from multiple DENV serotypes, indicating the activation of cross-reactive cellular immunity. While broad immune recognition was achieved, this was accompanied by lower serotype-specific response magnitudes as a trade-off. In conclusion, the cNS1 mRNA vaccine induces cross-serotype humoral and cellular immune responses in mice, highlighting the potential of consensus antigen design to broaden immune recognition of DENV NS1. These findings support the further development of NS1-based immunogens as complementary components of next-generation dengue vaccines aimed at achieving broad and effective protection.
Kittipan Tharakhet, E. Prompetchara, Chirayus Khawsang et al.· PLoS ONE· 0 citations
An mRNA vaccine encoding tandem CD8+ T-cell epitopes with optimized flanking sequences elicited quantitatively and qualitatively superior epitope-specific CD8+ responses in HLA-A*02:01 mice and in PBMCs from people with HIV-1.
T. Nogimori, H. Nguyen, M. Kumamoto et al.· Journal of Immunology· 0 citations
Self-amplifying mRNA (samRNA) vaccines can induce potent immune responses at lower doses than conventional non-replicating mRNA vaccines; however, large RNA size and manufacturing considerations associated with 5' capping remain important challenges. Here, we developed a capless samRNA (CLsamRNA) vaccine platform derived from a Coxsackievirus B5 replicon that uses IRES-mediated cap-independent translation. Systematic optimization of key genetic elements enhanced antigen expression from the CLsamRNA backbone. Using reporter RNAs, LNP-formulated CLsamRNA showed rapid early expression and RNA amplification, with expression kinetics distinct from VEEV-based saRNA and nucleoside-modified mRNA comparators. When encoding the hemagglutinin antigen of highly pathogenic avian influenza clade 2.3.4.4 H5 viruses, CLsamRNA induced potent immune responses after LNP formulation. In mouse models, CLsamRNA induced potent neutralizing antibody responses, cross-reactive activity against clade 2.3.4.4b H5N1 virus, Th1-skewed humoral immunity, and strong antigen-specific cellular immune responses. CLsamRNA also elicited platform-specific early inflammatory and lymph-node immune gene signatures associated with antigen presentation, costimulation, and cellular immune priming. Notably, a minimal 0.01 μg dose of CLsamRNA conferred complete protection against lethal H5N8 influenza virus challenge in BALB/c mice. These findings support CLsamRNA as a distinct cap-independent RNA vaccine platform with dose-sparing protective efficacy against HPAI H5 viruses.
Beom Kyu Kim, Ji-Hyun Park, Won-Suk Choi et al.· Molecular Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
